Fuda Cancer Hospital is one of the leading cancer hospitals in China and enjoys the trust of a large number of patients across the world. The hospital is affiliated with Jinan University and the Translational Medicine Center of Guangzhou Institute of Biomedicine and Health, which is under the Chinese Academy of Sciences.
As a tertiary (top-level) hospital, FUDA operates as a top-level (tertiary) hospital with international compliance and standards, which it was chosen for in 2010, naming Oncology as a National Key Clinical Specialty.

The institution has in its custody 400 beds, which comprise 45 VIP rooms, and a total of 500 medical personnel for patient care. Apart from this, FUDA has offices in India, in the cities of Delhi and Mumbai, where it works through Rekosh Healthcare Pvt. Ltd. in aiding Indian patients. 

FUDA takes pride in giving equal importance to research endeavors and direct patient services. Over the past twenty years, it has emerged as a leader in Minimally Invasive Cancer Treatments like Cryosurgery, NanoKnife, and Brachytherapy. FUDA remains the sole hospital in Asia using NanoKnife for cancer treatment, earning extensive experience in the process.

FUDA provides a nurturing atmosphere in which numerous patients can stay with their relatives during the course of treatment. The hospital has, to date, attended to in excess of 10,000 patients from over 100 countries, of which approximately 50% are patients from South-East Asia, the Middle East, Oceania, Europe, and North America.

This hospital centers on the use of Minimally Invasive techniques for surgery which assists in treating more patients than any other hospital in the world, and the hospital has also won numerous awards both nationally in China and internationally, while receiving praise from global patients.